TNF-α blockers for the treatment of Kawasaki disease in children-Reference-Cited by-同舟云学术

TNF-α blockers for the treatment of Kawasaki disease in children

Published:2019-08-16 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Yamaji Noyuri¹,da Silva Lopes Katharina²,Shoda Tetsuo³,Ishitsuka Kazue⁴,Kobayashi Tohru⁵,Ota Erika¹,Mori Rintaro⁶

Affiliation:

1. St. Luke's International University; Global Health Nursing, Graduate School of Nursing Sciences; 10-1 Akashi-cho Chuo-Ku Tokyo MS Japan 104-0044

2. St. Luke's International University; Graduate School of Public Health; 3-6-2 Tsukiji Chuo-Ku Tokyo MS Japan 104-0045

3. Cincinnati Children's Hospital Medical Center; Division of Allergy & Immunology; 240 Albert Sabin Way Cincinnati USA 45229

4. National Center for Child Health and Development; Department of General Paediatrics and Interdisciplinary Medicine; 2-10-1 Okura Setagaya Tokyo Tokyo Japan 157-8535

5. National Center for Child Health and Development; Department of Development Strategy; 2-10-1 Okura Setagaya Tokyo Tokyo Japan 157-8535

6. National Center for Child Health and Development; Department of Health Policy; 2-10-1 Okura Setagaya-ku Tokyo Tokyo Japan 157-0074

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012448.pub2/epdf/full

Reference81 articles.

1. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease;Burns;Journal of Pediatrics,2008

2. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin;Burns;Clinical and Experimental Immunology,2013

3. NCT00271570 Infliximab (Remicade) for patients with acute Kawasaki disease clinicaltrials.gov/ct2/show/NCT00271570

4. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial;Mori;Scientific Reports,2018

5. Mori M Hara T Kikuchi M Shimizu H Miyamoto T Iwashima S Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Supplementary information Available from https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-017-18387-7/MediaObjects/41598_2017_18387_MOESM1_ESM.pdf

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma proteomic profiling reveals that SERPINE1 is a potential biomarker associated with coronary artery lesions in Kawasaki disease;International Immunopharmacology;2024-09

2. Prediction of intravenous immunoglobulin retreatment in children with Kawasaki disease using models combining lymphocyte subset and cytokine profile in an East Asian cohort;Clinical & Translational Immunology;2024-01

3. Immunoglobulin-resistant Kawasaki disease;Boletín Médico del Hospital Infantil de México;2023-09-13

4. A pilot study of the differentiated landscape of peripheral blood mononuclear cells from children with incomplete versus complete Kawasaki disease;World Journal of Pediatrics;2023-09-09

5. TBBPA causes inflammation and cell death via the ROS/NF-κB pathway in the gastric mucosa;Ecotoxicology and Environmental Safety;2023-09